北京商报讯（记者 郭秀娟 王悦彤） 1月6日，湘佳股份发布公告称，2025年12月份销售活禽444.24万 只，销售收入1.04亿元，销售均价10.71元/公斤，环比变动分别为21.94%、22.57%、-0.04%，同比变动 分别为3.15%、20.17%、11.55%。2025年度销售活禽4756.02万只，销售收入9.52亿元，销售均价9.82元/ 公斤，同比变动分别为5.04%、-2.79%、-8.91%。 ...

北京商报讯（记者 郭秀娟 王悦彤） 1月6日，新希望在投资者互动平台回答投资者提问称，公司在2025 年响应国家去产能政策号召，主动调整了针对闲置场线的复产计划，因此仍然要承担着闲置产能带来的 一定影响，但相信在全行业共同推动下，如果产能能确实降低，带来猪价上涨，对全行业也是有益的。 公司12月底的能繁母猪存栏数已经降至75万头以下。 ...

Core Viewpoint - Shennong Group reported a decline in pig sales prices and overall sales volume for December 2025, indicating potential challenges in the market [1] Sales Performance - In December 2025, the company sold 314,100 pigs, including 287,300 commercial pigs and 14,100 piglets, generating sales revenue of 428 million yuan [1] - For the entire year of 2025, the company sold a total of 3,074,200 pigs, comprising 2,638,200 commercial pigs and 364,700 piglets, with total sales revenue reaching 4.729 billion yuan [1] Pricing Trends - The average selling price of commercial pigs in December 2025 was 11.08 yuan per kilogram, reflecting a decrease of 3.15% compared to November 2025 [1] - The company sold 49,800 pigs to its internal slaughtering enterprises in December 2025 [1]

Core Viewpoint - Baili Tianheng (688506) announced that its self-developed, first-in-class EGFR×HER3 dual antibody ADC (injectable iza-bren) has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - Iza-bren is the world's first EGFR×HER3 dual antibody ADC to be included in the priority review list [1] - As of now, iza-bren has been recognized as a breakthrough therapy for recurrent or metastatic esophageal squamous cell carcinoma that has failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] - The interim analysis for the Phase III clinical trial of iza-bren has achieved dual primary endpoints of progression-free survival (PFS) and overall survival (OS) [1] Group 2 - Iza-bren has two indications that have been included in the priority review list by the NMPA [1]

Core Viewpoint - The company is accelerating its internationalization and innovation efforts, with over 170 products included in the 2025 National Medical Insurance Directory, and is focusing on expanding its global market presence through strategic partnerships and product registrations [1][3][4]. Group 1: Product Development and Innovation - The company has 73 exclusive products in the 2025 National Medical Insurance Directory, including 63 traditional Chinese medicines, 9 chemical drugs, and 1 vaccine [1]. - The company is advancing its first-class new drug, Efparepoetin alfa, which has a cumulative R&D investment of approximately 51.24 million RMB as of September 30, 2025, and is expected to have significant market potential as it is the first of its kind in China [3]. - The company has successfully registered multiple products in various countries, including Malaysia, Canada, and Mongolia, indicating a strong international market strategy [5][6]. Group 2: Policy Support and Market Expansion - A recent guideline issued by five government departments aims to enhance the overseas service ecosystem for Chinese enterprises, which will support the company's international expansion efforts [4]. - The company has expanded its product sales to numerous countries and regions, including the United States, Canada, and several countries in Asia, Europe, and Africa, with ongoing registration efforts in Australia, Brazil, and the UAE [5]. Group 3: Corporate Social Responsibility - The company has contributed nearly 33 billion RMB in taxes, supporting local economic development and demonstrating its commitment to social responsibility [7]. - The "Together, Build a Chinese Heart" project has been ongoing for 18 years, providing medical assistance to Tibetan and minority communities, showcasing the company's dedication to social welfare [8][10]. - The company emphasizes long-term commitment to public welfare, aiming to set an industry example in corporate citizenship [7][10].

Core Viewpoint - The company, Siwei Control (603508), announced the termination of a significant control change plan involving its major shareholders due to a lack of consensus on key terms, leading to the resumption of its stock trading on January 7 [1] Group 1 - The major shareholders, Li Xin, Guo Jie, and Wang Weiping, decided to terminate the control change plan after careful consideration and negotiation [1] - The termination of the control change plan will not have a significant adverse impact on the company's operational performance and financial status [1] - The company confirmed that its business operations remain normal despite the termination of the control change plan [1]

Core Points - January marks the peak season for outdoor ice skating in Beijing, with various ice rinks opening to cater to different visitor needs [1][3] Group 1: Ice Rink Highlights - The Yuanmingyuan Ice Rink has launched its fifth annual ice and snow season, featuring a blend of historical ambiance and diverse activities [3] - The Fuhai Ice Rink offers a vast 50,000 square meters of ice surface, with classic activities like single and double ice cars, and upgraded ice skate rental services [4] - The Fenglinzhou Ice Rink emphasizes family interaction, featuring popular activities such as electric dog sledding and an expanded snow park with 46 slides [4] Group 2: Additional Ice Rink Features - The Xihai Ice Rink, covering 2,200 square meters, provides unlimited playtime and nostalgic activities, including a new 75-meter long ice slide [5] - The Fengtai Garden Ice Rink spans over 1,500 square meters, accommodating over 150 people, and introduces fun competitions like curling and tug-of-war [6] - The Lianhua Pond Ice Rink offers a beginner-friendly area and various ice vehicles, ensuring a safe and enjoyable experience for families [7] Group 3: Unique Offerings - The Tuanjiehu Park Ice Rink features over ten types of ice vehicles and electric ice activities, along with nearby dining options for visitors [8] - The Xibeiwang Wanxianghui Ice Rink combines shopping and ice skating, featuring a unique miniature Iceland-themed attraction [9] - The Changping Park Ice Rink provides a wide range of activities suitable for all ages, including ice bicycles and a free policy for children under one meter tall [10] Group 4: Special Events and Facilities - The Shougang Park "Show Ice Rink" features a massive 30,000 square meters of ice surface and over 300 ice equipment options, enhancing visitor experience with flexible operating hours [11] - The ice rinks are subject to weather conditions, and visitors are encouraged to check for updates on operational status [11]

百花医药表示，由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意 见，本着审慎的原则，决定终止本次控制权变更事项。公司目前各项经营情况正常，终止筹划控制权变 更事项不会对公司经营业绩和财务状况产生重大不利影响。 北京商报讯（记者 丁宁）1月6日晚间，百花医药（600721）发布公告称，因公司控股股东、实际控制 人米在齐、米恩华、杨小玲终止筹划本次控制权变更事项，经公司向上交所申请，公司股票将于1月7日 开市起复牌。 ...

北京商报讯港交所官网显示，1月5日，爷爷的农场国际控股有限公司（以下简称"爷爷的农场"）已递交 上市申请书，正式向港股发起冲击。 财务数据显示，2025年前三季度，爷爷的农场实现收入约为7.8亿元，婴童零辅食贡献收入占比达到八 成。 （文章来源：北京商报） 据了解，爷爷的农场是中国婴童零辅食行业的领导者，并已拓展至中国家庭食品行业，公司于2018年推 出了首款婴童辅食产品。 根据弗若斯特沙利文的资料，爷爷的农场已成长为中国婴童零辅食市场的领军品牌，按2024年中国婴童 零辅食商品交易总额计算，爷爷的农场排名第二，且在商品交易总额排名前五的公司中，爷爷的农场于 2022年至2024年实现最高复合年增长率；而按2024年中国有机婴童零辅食的商品交易总额计，爷爷的农 场排名第一。 ...

Core Insights - The article highlights the shift in the Beijing real estate market towards a "value choice model" for improvement-type housing, with a significant number of new projects entering the market in 2025 [1][3] - The performance of these projects varies greatly, with some achieving high sales rates while others struggle due to factors like product positioning and location [5][10] Group 1: Market Overview - In 2025, there will be 26 improvement-type projects in Beijing priced between 60,000 to 100,000 yuan per square meter, supplying over 13,000 units [1][3] - The top-performing project, Zhongjian · Yunhe Jiuyuan, achieved a sales rate of 81.15%, while another project, China Overseas Chaoyang ONE, only reached 14.48% [1][3][5] Group 2: Project Performance - Zhongjian · Yunhe Jiuyuan's first phase sold 680 out of 838 units, while its second phase, launched in December, has already signed 242 out of 552 units, achieving a 43.84% sales rate [3][4] - Other projects like Yihai Luansong and Jianfa Jinmao Guancheng also performed well, with sales rates exceeding 70% [4][10] Group 3: Design and Location Impact - The design flaws in projects like China Overseas Chaoyang ONE, particularly in unit layout and space efficiency, have hindered their sales performance [6][7][8] - Location and surrounding amenities significantly influence project sales, with better-located projects like Yihai Luansong outperforming others despite higher prices [9][10] Group 4: Future Considerations - Developers are advised to focus on six core dimensions, including mature amenities, safety in building design, and optimizing unit layouts to enhance market appeal [11]